Abstract Background In 2009, Norway initiated routine quadrivalent HPV (qHPV) vaccination
for girls at 12–13 years of age to protect against virus types causing cervical cancer …

Abstract Background In 2009, both Norway and Denmark initiated routine quadrivalent
human papillomavirus vaccination (qHPV) for 12-year-old girls; however, Denmark also …

Objective The aim of the study was to investigate the effects of 3 or less quadrivalent human
papillomavirus (HPV) vaccine doses on anogenital warts in both males and females in the …

Background There is ongoing debate about the possible protective effect of the bivalent
human papillomavirus (2vHPV) vaccine, targeting oncogenic types HPV-16/18, against …

Genital warts (GWs) are common, with about 5% to 10% of people having at least one
episode in their lifetime. They develop about 2–3 months after infection with human …

Background Decision-makers may consider vaccinating girls and boys with different HPV
vaccines to benefit from their respective strengths; the quadrivalent (HPV4) prevents …

Background Assessing the impact and effectiveness of HPV vaccines on anogenital warts in
the United States can provide early indication of the success of vaccination programs as well …

Publicly funded administration of the quadrivalent HPV (qHPV) vaccine in school-aged girls
was implemented for all Canadian provinces and territories between 2007 and 2009 …

Background Increasing evidence suggests that 1-dose human papillomavirus (HPV)
vaccination may protect significantly against HPV-related disease. We provide nationwide …

Background HPV is related to a number of cancer types, causing a considerable burden in
both genders in Europe. Female vaccination programs can substantially reduce the …